Fatimah Alyami
Center for Health Technology Assessment, Center for National Health Insurance
Fatimah Alyami is listed at Center for Health Technology Assessment, Center for National Health Insurance. Fatimah spoke at ISPOR Europe 2026 in November 2026 (speaker, “Beyond Pricing: How HTA Informs Health System Decisions Worldwide”). Speaks mainly at Government Administration events.
Compiled from published conference agendas; not yet confirmed by Fatimah. Is this you? Claim this profile.
- Sector: Government Administration
About
Dr. Fatimah Alyami is a senior health economist and licensed senior pharmacist with over a decade of multidisciplinary experience spanning health economics, health technology assessment (HTA), pharmaceutical policy, and clinical pharmacy. She currently serves as Health Economic Assessment Senior Specialist at the Center of Health Technology Assessment within the Center for National Health Insurance (CNHI), where she leads the design and appraisal of economic evaluations, value-based healthcare models, and evidence-based policy strategies tailored to the Saudi healthcare system. Dr. Alyami holds a PhD in Pharmaceutical Science (Health Outcomes) from the University of Cincinnati, along with dual master’s degrees in Pharmaceutical Economics & Policy and Pharmaceutical Outcomes & Policy. She is an active member of ISPOR, ISPE, and the Saudi Pharmaceutical Society, with research presented at leading international conferences and published in peer-reviewed journals. Recognized for he
Sessions at 1 conference
ISPOR Europe 2026 8 November 2026 – 11 November 2026
- Beyond Pricing: How HTA Informs Health System Decisions Worldwide Speaker · 10 November 2026
Spoke alongside
People who have shared a session with Fatimah at events on B2DB.
- Claire Telford Senior Director, Value & Evidence Team Lead, Method’s Innovation · Pfizer Inc. 1 shared session
- Jessica Daw Sentara Health Plans 1 shared session
- Joseph Mfutso-Bengo Professor · Kamuzu University of Health Sciences 1 shared session
- Sudha Kutty Executive Vice President, Evidence Products and Services · Canada’s Drug Agency 1 shared session